Francesco Pellegrino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francesco Pellegrino has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
Alberto Briganti
Division of Oncology/Unit of Urology, Soldera Prostate Cancer Lab, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
18 shared publicationsFrancesco Montorsi
Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy
13 shared publications- Francesco Montorsi
Vita-Salute San Raffaele University, Milan, Italy
13 shared publications Giorgio Gandaglia
Division of Oncology/Unit of Urology, Urological Research Institute IRCCS Ospedale San Raffaele Milan Italy
10 shared publications- Armando Stabile
Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
9 shared publications - Alberto Briganti
Vita-Salute San Raffaele University
8 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Elsevier in European Urology Oncology
Individualized Oncologic Surveillance After Radical Prostatectomy for Localized Prostate Cancer
- 25 September 2026
- Published by Elsevier in European Urology Oncology
Open AccessIndividualized Oncologic Surveillance After Radical Prostatectomy for Localized Prostate Cancer
- Open Access
- 23 September 2026
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- p. 1-8
PHI for adverse pathology and PHI density for upgrading: two complementary predictors in localized prostate cancer
Background: The Prostate Health Index (PHI) has emerged as a promising biomarker for improving prostate cancer (PCa) detection. However, its role in predicting pathological aggressiveness at radical prostatectomy (RP) requires further elucidation. We aimed to assess the ability of PHI and PHI density (PHId) to predict adverse pathological features and ISUP upgrading in men undergoing robot-assisted RP. Methods: We conducted a prospective, single-center observational study including 130 patients who underwent RP. Total PSA, free PSA, and p2PSA were measured using the Access 2 platform, and PHI and PHId were calculated accordingly. Multivariable logistic regression models evaluated the association of PSA, PSA density, PHI, and PHId with two predefined endpoints: (i) adverse pathological features (pT ≥3 and/or pN1), and (ii) upgrading from biopsy to RP. Models were adjusted for DRE status, PI-RADS score, and biopsy ISUP grade. Discrimination was assessed using AUC and the DeLong test. Results: Median PSA, PHI, PSA density, and PHId were 6.21 ng/mL, 58, 0.15 ng/mL/cc, and 1.40, respectively. Adverse pathological features were identified in 39% of cases, and upgrading occurred in 59% (after exclusion of biopsy ISUP 5 cases). PHI emerged as the strongest independent predictor of adverse pathology (OR 1.04; 95% CI 1.02–1.07), yielding the highest model accuracy (AUC 0.86) and showing a sharp risk increase above PHI > 40. PHId was the only marker independently associated with upgrading (OR 1.54; 95% CI 1.10–2.29), achieving the best discrimination (AUC 0.83), with risk escalation particularly evident in patients with PI-RADS 4–5 lesions. Conclusions: PHI and PHId provide complementary information in localized PCa. PHI accurately identifies patients at risk of adverse pathological extension, whereas PHId effectively captures the probability of grade reclassification at RP. Integrating these biomarkers into patient assessment may support precision-based decision-making and helping to minimize undertreatment.
- 23 September 2026
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- p. 1-8
Open AccessPHI for adverse pathology and PHI density for upgrading: two complementary predictors in localized prostate cancer
Background: The Prostate Health Index (PHI) has emerged as a promising biomarker for improving prostate cancer (PCa) detection. However, its role in predicting pathological aggressiveness at radical prostatectomy (RP) requires further elucidation. We aimed to assess the ability of PHI and PHI density (PHId) to predict adverse pathological features and ISUP upgrading in men undergoing robot-assisted RP. Methods: We conducted a prospective, single-center observational study including 130 patients who underwent RP. Total PSA, free PSA, and p2PSA were measured using the Access 2 platform, and PHI and PHId were calculated accordingly. Multivariable logistic regression models evaluated the association of PSA, PSA density, PHI, and PHId with two predefined endpoints: (i) adverse pathological features (pT ≥3 and/or pN1), and (ii) upgrading from biopsy to RP. Models were adjusted for DRE status, PI-RADS score, and biopsy ISUP grade. Discrimination was assessed using AUC and the DeLong test. Results: Median PSA, PHI, PSA density, and PHId were 6.21 ng/mL, 58, 0.15 ng/mL/cc, and 1.40, respectively. Adverse pathological features were identified in 39% of cases, and upgrading occurred in 59% (after exclusion of biopsy ISUP 5 cases). PHI emerged as the strongest independent predictor of adverse pathology (OR 1.04; 95% CI 1.02–1.07), yielding the highest model accuracy (AUC 0.86) and showing a sharp risk increase above PHI > 40. PHId was the only marker independently associated with upgrading (OR 1.54; 95% CI 1.10–2.29), achieving the best discrimination (AUC 0.83), with risk escalation particularly evident in patients with PI-RADS 4–5 lesions. Conclusions: PHI and PHId provide complementary information in localized PCa. PHI accurately identifies patients at risk of adverse pathological extension, whereas PHId effectively captures the probability of grade reclassification at RP. Integrating these biomarkers into patient assessment may support precision-based decision-making and helping to minimize undertreatment.
- 13 October 2025
- Published by Wiley in BJU International
- Vol. 137 (2) , 282-288
Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging‐Reporting and Data System and biopsy history
Objective: To investigate the diagnostic performance of perilesional biopsies (PLBx) compared to other biopsy strategies, assessing the impact of the Prostate Imaging‐Reporting and Data System (PI‐RADS) score and biopsy history in patients with a visible lesion at multiparametric magnetic resonance imaging of the prostate (mpMRI), as the European Association of Urology guidelines recommend combining MRI‐targeted biopsies (TBx) with PLBx as an alternative to systematic biopsies (SBx) even though evidence is limited. Patients and Methods: We relied on a cohort of 2852 patients with PI‐RADS ≥3 lesions undergoing TBx + SBx at three tertiary referral centres. The primary outcome was detection of clinically significant PCa (csPCa) (International Society of Urological Pathology Grade Group [ISUP GG] ≥2) of TBx + PLBx vs TBx + SBx. Results were stratified by PI‐RADS score and biopsy history. The PLBx cores were defined as samples taken from prostate sectors adjacent to the mpMRI lesion. We finally assessed insignificant PCa (insPCa, i.e., ISUP GG 1) detection across biopsy strategies. Differences were assessed using the chi‐square test. Results: Detection of csPCa was 48%. Overall, TBx + SBx had a higher csPCa detection rate than TBx + PLBx (50% vs 45%, P = 0.03), particularly in PI‐RADS 3 lesions (26% vs 21%, P = 0.02) and active surveillance (AS) patients (46% vs 40%, P = 0.04). No significant differences were found in PI‐RADS 4 (53% vs 50%, P > 0.1) or PI‐RADS 5 (76% vs 75%, P > 0.1). In the biopsy naïve and previous negative biopsy groups, csPCa detection was similar between strategies ( P > 0.1). Conclusions: Overall, TBx + SBx offers the highest detection of csPCa. Even though TBx + PLBx may be considered in PI‐RADS 4–5 lesions to reduce insPCa detection, TBx + SBx remains the preferred strategy for PI‐RADS 3 and AS patients.
- 13 October 2025
- Published by Wiley in BJU International
- Vol. 137 (2) , 282-288
Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging‐Reporting and Data System and biopsy history
Objective: To investigate the diagnostic performance of perilesional biopsies (PLBx) compared to other biopsy strategies, assessing the impact of the Prostate Imaging‐Reporting and Data System (PI‐RADS) score and biopsy history in patients with a visible lesion at multiparametric magnetic resonance imaging of the prostate (mpMRI), as the European Association of Urology guidelines recommend combining MRI‐targeted biopsies (TBx) with PLBx as an alternative to systematic biopsies (SBx) even though evidence is limited. Patients and Methods: We relied on a cohort of 2852 patients with PI‐RADS ≥3 lesions undergoing TBx + SBx at three tertiary referral centres. The primary outcome was detection of clinically significant PCa (csPCa) (International Society of Urological Pathology Grade Group [ISUP GG] ≥2) of TBx + PLBx vs TBx + SBx. Results were stratified by PI‐RADS score and biopsy history. The PLBx cores were defined as samples taken from prostate sectors adjacent to the mpMRI lesion. We finally assessed insignificant PCa (insPCa, i.e., ISUP GG 1) detection across biopsy strategies. Differences were assessed using the chi‐square test. Results: Detection of csPCa was 48%. Overall, TBx + SBx had a higher csPCa detection rate than TBx + PLBx (50% vs 45%, P = 0.03), particularly in PI‐RADS 3 lesions (26% vs 21%, P = 0.02) and active surveillance (AS) patients (46% vs 40%, P = 0.04). No significant differences were found in PI‐RADS 4 (53% vs 50%, P > 0.1) or PI‐RADS 5 (76% vs 75%, P > 0.1). In the biopsy naïve and previous negative biopsy groups, csPCa detection was similar between strategies ( P > 0.1). Conclusions: Overall, TBx + SBx offers the highest detection of csPCa. Even though TBx + PLBx may be considered in PI‐RADS 4–5 lesions to reduce insPCa detection, TBx + SBx remains the preferred strategy for PI‐RADS 3 and AS patients.
- Open Access
- 15 July 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (10) , 110326
Pelvic lymph-node dissections in bladder and prostate cancer surgery and the risk of postoperative venous thromboembolism
- 15 July 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (10) , 110326
Open AccessPelvic lymph-node dissections in bladder and prostate cancer surgery and the risk of postoperative venous thromboembolism
- 2 June 2025
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (1) , 111-115
Tailored use of PSA density according to multiparametric MRI index lesion location: results of a large, multi-institutional series
Background The use of prostate-specific antigen density (PSAd) in combination with multiparametric magnetic resonance imaging (mpMRI) of the prostate can improve accuracy of the prostate cancer (PCa) diagnostic pathway. However, it is not clear whether the performance characteristics of PSAd vary according to the index lesion location (ILL) on mpMRI. Methods Overall, 2140 patients with positive mpMRI (prostate imaging reporting and data system [PI-RADS] ≥ 3) underwent mpMRI-targeted biopsy (TBx) plus systematic biopsy (SBx) at three tertiary referral centers. Multivariable logistic regression analysis (MVA) tested the interaction between PSAd and ILL (peripheral zone [PZ] vs transitional zone [TZ]) in predicting clinically significant PCa (csPCa, defined as ISUP grade group ≥2) at TBx. Non-parametric locally weighted scatterplots smoothing approach (LOWESS) explored the relationship between PSAd and csPCa according to ILL and stratifying by PI-RADS score. Results Median PSA was 6.7 ng/ml. ILL was PZ and TZ in 77% and 23% patients, respectively. Overall, 39% of csPCa cases were diagnosed at TBx. The association between PSAd and csPCa varied according to ILL (interaction test: p < 0.01). In patients with PI-RADS 3 lesions, csPCa incidence was <10% in cases of PSAd values < 0.05 ng/ml/ml and <0.13 ng/ml/ml for PZ and TZ lesions, respectively. Differently, in patients with PI-RADS ≥ 4, csPCa incidence was ≥20% regardless of PSAd value and ILL. Conclusions The likelihood of detecting csPCa in patients with PI-RADS 3 lesions is influenced by the combination of PSAd and ILL. Specifically, patients with PZ and TZ PI-RADS 3 lesions have an increased risk of csPCa for PSAd values ≥ 0.05 ng/ml/ml and ≥0.13 ng/ml/ml, respectively. Conversely, patients with PI-RADS ≥ 4 lesions have a non-negligible risk of csPCa regardless of PSAd and ILL.
- 2 June 2025
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (1) , 111-115
Tailored use of PSA density according to multiparametric MRI index lesion location: results of a large, multi-institutional series
Background The use of prostate-specific antigen density (PSAd) in combination with multiparametric magnetic resonance imaging (mpMRI) of the prostate can improve accuracy of the prostate cancer (PCa) diagnostic pathway. However, it is not clear whether the performance characteristics of PSAd vary according to the index lesion location (ILL) on mpMRI. Methods Overall, 2140 patients with positive mpMRI (prostate imaging reporting and data system [PI-RADS] ≥ 3) underwent mpMRI-targeted biopsy (TBx) plus systematic biopsy (SBx) at three tertiary referral centers. Multivariable logistic regression analysis (MVA) tested the interaction between PSAd and ILL (peripheral zone [PZ] vs transitional zone [TZ]) in predicting clinically significant PCa (csPCa, defined as ISUP grade group ≥2) at TBx. Non-parametric locally weighted scatterplots smoothing approach (LOWESS) explored the relationship between PSAd and csPCa according to ILL and stratifying by PI-RADS score. Results Median PSA was 6.7 ng/ml. ILL was PZ and TZ in 77% and 23% patients, respectively. Overall, 39% of csPCa cases were diagnosed at TBx. The association between PSAd and csPCa varied according to ILL (interaction test: p < 0.01). In patients with PI-RADS 3 lesions, csPCa incidence was <10% in cases of PSAd values < 0.05 ng/ml/ml and <0.13 ng/ml/ml for PZ and TZ lesions, respectively. Differently, in patients with PI-RADS ≥ 4, csPCa incidence was ≥20% regardless of PSAd value and ILL. Conclusions The likelihood of detecting csPCa in patients with PI-RADS 3 lesions is influenced by the combination of PSAd and ILL. Specifically, patients with PZ and TZ PI-RADS 3 lesions have an increased risk of csPCa for PSAd values ≥ 0.05 ng/ml/ml and ≥0.13 ng/ml/ml, respectively. Conversely, patients with PI-RADS ≥ 4 lesions have a non-negligible risk of csPCa regardless of PSAd and ILL.
- Open Access
The Role of Robot-Assisted, Imaging-Guided Surgery in Prostate Cancer Patients
Emerging imaging-guided technologies, such as prostate-specific membrane antigen radioguided surgery (PSMA-RGS) and augmented reality (AR), could enhance the precision and efficacy of robot-assisted prostate cancer (PCa) surgical approaches, maximizing the surgeons’ ability to remove all cancer sites and thus patients’ outcomes. Sentinel node biopsy (SNB) represents an imaging-guided technique that could enhance nodal staging accuracy by leveraging lymphatic mapping with tracers. PSMA-RGS uses radiolabeled tracers with the aim to improve intraoperative lymph node metastases (LNMs) detection. Several studies demonstrated its feasibility and safety, with promising accuracy in nodal staging during robot-assisted radical prostatectomy (RARP) and in recurrence setting during salvage lymph node dissection (sLND) in patients who experience biochemical recurrence (BCR) after primary treatment and have positive PSMA positron emission tomography (PET). Near-infrared PSMA tracers, such as OTL78 and IS-002, have shown potential in intraoperative fluorescence-guided surgery, improving positive surgical margins (PSMs) and LNMs identification. Finally, augmented reality (AR), which integrates preoperative imaging (e.g., multiparametric magnetic resonance imaging [mpMRI] of the prostate and computed tomography [CT]) onto the surgical field, can provide a real-time visualization of anatomical structures through the creation of three-dimensional (3D) models. These technologies may assist surgeons during intraoperative procedures, thus optimizing the balance between oncological control and functional outcomes. However, challenges remain in standardizing these tools and assessing their impact on long-term PCa control. Overall, these advancements represent a paradigm shift toward personalized and precise surgical approaches, emphasizing the integration of innovative strategies to improve outcomes of PCa patients.
Open AccessThe Role of Robot-Assisted, Imaging-Guided Surgery in Prostate Cancer Patients
Emerging imaging-guided technologies, such as prostate-specific membrane antigen radioguided surgery (PSMA-RGS) and augmented reality (AR), could enhance the precision and efficacy of robot-assisted prostate cancer (PCa) surgical approaches, maximizing the surgeons’ ability to remove all cancer sites and thus patients’ outcomes. Sentinel node biopsy (SNB) represents an imaging-guided technique that could enhance nodal staging accuracy by leveraging lymphatic mapping with tracers. PSMA-RGS uses radiolabeled tracers with the aim to improve intraoperative lymph node metastases (LNMs) detection. Several studies demonstrated its feasibility and safety, with promising accuracy in nodal staging during robot-assisted radical prostatectomy (RARP) and in recurrence setting during salvage lymph node dissection (sLND) in patients who experience biochemical recurrence (BCR) after primary treatment and have positive PSMA positron emission tomography (PET). Near-infrared PSMA tracers, such as OTL78 and IS-002, have shown potential in intraoperative fluorescence-guided surgery, improving positive surgical margins (PSMs) and LNMs identification. Finally, augmented reality (AR), which integrates preoperative imaging (e.g., multiparametric magnetic resonance imaging [mpMRI] of the prostate and computed tomography [CT]) onto the surgical field, can provide a real-time visualization of anatomical structures through the creation of three-dimensional (3D) models. These technologies may assist surgeons during intraoperative procedures, thus optimizing the balance between oncological control and functional outcomes. However, challenges remain in standardizing these tools and assessing their impact on long-term PCa control. Overall, these advancements represent a paradigm shift toward personalized and precise surgical approaches, emphasizing the integration of innovative strategies to improve outcomes of PCa patients.
- 26 March 2025
- Published by Wiley in BJU International
- Vol. 136 (2) , 336-343
The impact of histopathological evaluation at transurethral resection of bladder tumour on survival in radical cystectomy candidates
Objective: To evaluate the impact of discordant histological diagnoses between transurethral resection of bladder tumour (TURBT) and radical cystectomy (RC) on cancer‐specific mortality (CSM) in patients with bladder cancer (BCa). Patients and Methods: We relied on a multi‐institutional database collecting data of patients with BCa who underwent TURBT and subsequent RC from nine centres between 2000 and 2023. We tested concordance rates between TURBT and RC in detecting urothelial carcinoma of the urinary bladder (UCUB) as well as non‐UCUB hystological subtypes, using RC as the reference standard. Concordance was defined as the agreement between a specific histological subtype identified both at TURBT and RC and evaluated according to Cohen's kappa coefficient. Subsequently, survival analyses consisted of Kaplan–Meier plots and multivariable Cox regression (MCR) models addressing CSM according to concordance between TURBT and RC (namely, concordant vs discordant). Results: Overall, 3160 patients were identified. Of these, 2762 (87%) harboured UCUB and 398 (13%) non‐UCUB at TURBT vs 2481 (79%) UCUB and 679 (21%) non‐UCUB at RC. There were 683 (21.6%) patients with a discordant diagnosis between TURBT and RC. The overall concordance in detecting non‐UCUB subtypes was defined as fair concordance (Cohen's kappa coefficient: 0.32). In MCR models, a discordant diagnosis exhibited higher CSM relative to those with a concordant diagnosis (hazard ratio [HR] 1.3, 95% confidence interval [CI] 1.1–1.6; P = 0.002). In a sensitivity analysis including patients with UCUB not exposed to neoadjuvant chemotherapy, this survival disadvantage was even higher (HR 1.5, 95% CI 1.1–1.7; P = 0.04). Conclusions: A discordant histopathological diagnosis between TURBT and RC is associated with higher CSM rates, particularly in cases initially misdiagnosed as UCUB. However, we also observed a moderate concordance between TURBT and RC in identifying non‐UCUB subtypes.
- 26 March 2025
- Published by Wiley in BJU International
- Vol. 136 (2) , 336-343
The impact of histopathological evaluation at transurethral resection of bladder tumour on survival in radical cystectomy candidates
Objective: To evaluate the impact of discordant histological diagnoses between transurethral resection of bladder tumour (TURBT) and radical cystectomy (RC) on cancer‐specific mortality (CSM) in patients with bladder cancer (BCa). Patients and Methods: We relied on a multi‐institutional database collecting data of patients with BCa who underwent TURBT and subsequent RC from nine centres between 2000 and 2023. We tested concordance rates between TURBT and RC in detecting urothelial carcinoma of the urinary bladder (UCUB) as well as non‐UCUB hystological subtypes, using RC as the reference standard. Concordance was defined as the agreement between a specific histological subtype identified both at TURBT and RC and evaluated according to Cohen's kappa coefficient. Subsequently, survival analyses consisted of Kaplan–Meier plots and multivariable Cox regression (MCR) models addressing CSM according to concordance between TURBT and RC (namely, concordant vs discordant). Results: Overall, 3160 patients were identified. Of these, 2762 (87%) harboured UCUB and 398 (13%) non‐UCUB at TURBT vs 2481 (79%) UCUB and 679 (21%) non‐UCUB at RC. There were 683 (21.6%) patients with a discordant diagnosis between TURBT and RC. The overall concordance in detecting non‐UCUB subtypes was defined as fair concordance (Cohen's kappa coefficient: 0.32). In MCR models, a discordant diagnosis exhibited higher CSM relative to those with a concordant diagnosis (hazard ratio [HR] 1.3, 95% confidence interval [CI] 1.1–1.6; P = 0.002). In a sensitivity analysis including patients with UCUB not exposed to neoadjuvant chemotherapy, this survival disadvantage was even higher (HR 1.5, 95% CI 1.1–1.7; P = 0.04). Conclusions: A discordant histopathological diagnosis between TURBT and RC is associated with higher CSM rates, particularly in cases initially misdiagnosed as UCUB. However, we also observed a moderate concordance between TURBT and RC in identifying non‐UCUB subtypes.
- 23 January 2025
- Published by Wiley in BJU International
- Vol. 136 (2) , 321-328
Immunotherapy‐based neoadjuvant treatment and complication rates after radical cystectomy
Objective: To assess 30‐ and 90‐day postoperative complication rates in patients who underwent robot‐assisted radical cystectomy (RARC) after receiving novel immunotherapy‐based neoadjuvant treatment. Methods: A bi‐centre analysis was conducted in patients who underwent RARC with intracorporeal urinary diversion and who received an immunotherapy‐based neoadjuvant regimen between 2017 and 2023. Complications were classified using the Clavien–Dindo system. Results: The cohort included 136 patients, with a median (interquartile range [IQR]) age of 66 (61–73) years, of whom 22 were female (16.2%). The overall 30‐day and 31–90‐day Clavien–Dindo grade ≥3a complication rates were 15.4%, and 14.7%, respectively. The most common cumulative 90‐day complications by category were infectious (59.6%), genitourinary (33.1%), and gastrointestinal (22.7%). The median (IQR) hospital stay was 11 (7–16) days, and 36 patients (26.5%) required readmission. Eighty‐four patients received monotherapy with an immune checkpoint inhibitor and 52 received combination immunochemotherapy. A higher rate of 30‐day infectious complications was seen in the immuno‐monotherapy group (46.4% vs 26.9%; P = 0.03), while pulmonary complications were more commonly reported in the combination immunochemotherapy group (9.6% vs 1.2%; P = 0.03). No statistically significant differences were found in the other complication categories between the groups. Eleven patients (8.1%) experienced 13 (9.6%) immune‐related adverse events (irAEs). The most common irAEs were hypothyroidism and dermatitis. Conclusions: The cumulative 90‐day complication rate after novel immunotherapy‐based neoadjuvant treatment appears higher than those previously reported for RARC alone or for chemotherapy‐based neoadjuvant regimens. We observed irAEs in 8.1% of patients after RARC, highlighting the need for urologists to recognise such events.
- 23 January 2025
- Published by Wiley in BJU International
- Vol. 136 (2) , 321-328
Immunotherapy‐based neoadjuvant treatment and complication rates after radical cystectomy
Objective: To assess 30‐ and 90‐day postoperative complication rates in patients who underwent robot‐assisted radical cystectomy (RARC) after receiving novel immunotherapy‐based neoadjuvant treatment. Methods: A bi‐centre analysis was conducted in patients who underwent RARC with intracorporeal urinary diversion and who received an immunotherapy‐based neoadjuvant regimen between 2017 and 2023. Complications were classified using the Clavien–Dindo system. Results: The cohort included 136 patients, with a median (interquartile range [IQR]) age of 66 (61–73) years, of whom 22 were female (16.2%). The overall 30‐day and 31–90‐day Clavien–Dindo grade ≥3a complication rates were 15.4%, and 14.7%, respectively. The most common cumulative 90‐day complications by category were infectious (59.6%), genitourinary (33.1%), and gastrointestinal (22.7%). The median (IQR) hospital stay was 11 (7–16) days, and 36 patients (26.5%) required readmission. Eighty‐four patients received monotherapy with an immune checkpoint inhibitor and 52 received combination immunochemotherapy. A higher rate of 30‐day infectious complications was seen in the immuno‐monotherapy group (46.4% vs 26.9%; P = 0.03), while pulmonary complications were more commonly reported in the combination immunochemotherapy group (9.6% vs 1.2%; P = 0.03). No statistically significant differences were found in the other complication categories between the groups. Eleven patients (8.1%) experienced 13 (9.6%) immune‐related adverse events (irAEs). The most common irAEs were hypothyroidism and dermatitis. Conclusions: The cumulative 90‐day complication rate after novel immunotherapy‐based neoadjuvant treatment appears higher than those previously reported for RARC alone or for chemotherapy‐based neoadjuvant regimens. We observed irAEs in 8.1% of patients after RARC, highlighting the need for urologists to recognise such events.
- 28 April 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-8
Peri- and post-operative outcomes of robot-assisted radical cystectomy after the implementation of the EAU guidelines recommendations for collecting and reporting complications at a high-volume referral center
Purpose No studies relied on a standardized methodology to collect postoperative complications after robot-assisted radical cystectomy (RARC). The aim of our study was to evaluate peri- and post-operative outcomes of patients undergoing RARC adhering to the European Association of Urology (EAU) recommendations for reporting surgical outcomes and using a long postoperative follow-up. Materials and methods 246 patients who underwent RARC with intracorporal urinary diversion at a single tertiary referral center with a postoperative follow-up ≥ 1 year for survivors. Postoperative outcomes were collected prospectively by interviews done by medical doctors. Complications were scored using the Clavien–Dindo classification (CD), grouped by type and severity (severe: CD score ≥ 3). We described peri- and post-operative outcomes and complication chronological distribution. Results Overall, 16 (6.5%) and 225 patients (91%) experienced intraoperative and postoperative complications, respectively. Moreover, 139 (57%) experienced severe complications. The most common any-grade and severe complications were infectious (72%) and genitourinary (35%), respectively. Overall, 52% of complications (358/682) occurred within 10 days from surgery, and 51% of severe complications (106/207) occurred within 35 days. However, 13% of complications (90/682) and 28% of severe complications (59/207) occurred 3 months after surgery. The earliest complications were fever of unknown origins and paralytic ileus (median time-to-complication [mTTC]: 4 days), the latest complications were urinary tract infection (mTTC: 40 days) and hydronephrosis/ureteral obstruction (mTTC: 70 days). Conclusions The rate of postoperative complications after RARC is > 90% when a standardized collection method and a long follow-up is implemented. These results should be used to identify potential areas of improvement and for preoperative patient counseling.
- 28 April 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-8
Peri- and post-operative outcomes of robot-assisted radical cystectomy after the implementation of the EAU guidelines recommendations for collecting and reporting complications at a high-volume referral center
Purpose No studies relied on a standardized methodology to collect postoperative complications after robot-assisted radical cystectomy (RARC). The aim of our study was to evaluate peri- and post-operative outcomes of patients undergoing RARC adhering to the European Association of Urology (EAU) recommendations for reporting surgical outcomes and using a long postoperative follow-up. Materials and methods 246 patients who underwent RARC with intracorporal urinary diversion at a single tertiary referral center with a postoperative follow-up ≥ 1 year for survivors. Postoperative outcomes were collected prospectively by interviews done by medical doctors. Complications were scored using the Clavien–Dindo classification (CD), grouped by type and severity (severe: CD score ≥ 3). We described peri- and post-operative outcomes and complication chronological distribution. Results Overall, 16 (6.5%) and 225 patients (91%) experienced intraoperative and postoperative complications, respectively. Moreover, 139 (57%) experienced severe complications. The most common any-grade and severe complications were infectious (72%) and genitourinary (35%), respectively. Overall, 52% of complications (358/682) occurred within 10 days from surgery, and 51% of severe complications (106/207) occurred within 35 days. However, 13% of complications (90/682) and 28% of severe complications (59/207) occurred 3 months after surgery. The earliest complications were fever of unknown origins and paralytic ileus (median time-to-complication [mTTC]: 4 days), the latest complications were urinary tract infection (mTTC: 40 days) and hydronephrosis/ureteral obstruction (mTTC: 70 days). Conclusions The rate of postoperative complications after RARC is > 90% when a standardized collection method and a long follow-up is implemented. These results should be used to identify potential areas of improvement and for preoperative patient counseling.